Industry

The Glioblastoma Foundation Launches Several Initiatives in Support of its National Commitment to Ensuring Accessible, Individualized Patient Care and Treatment DURHAM, N.C.–(BUSINESS WIRE)–Glioblastoma Awareness Day observed today, July 20, 2022, aims to increase public awareness of glioblastoma and honor those who have lost their lives to the devastating disease. In conjunction with the observance, the … [Read more…]

DALLAS & NEW YORK–(BUSINESS WIRE)–Signify Health, Inc. (NYSE: SGFY), a leading value-based healthcare platform enabled by advanced analytics, technology and nationwide healthcare networks, announced that it will release its financial results for the second quarter 2022 after the market closes on Wednesday, August 3, 2022, and will hold a conference call at 8:30am ET on … [Read more…]

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of … [Read more…]

KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on treatment resistant PTSD VANCOUVER, British Columbia–(BUSINESS WIRE)–$KONEF #ketamine–Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital … [Read more…]

The Genomic Test Demonstrated 100 Percent Sensitivity and 100 Percent Specificity for MTC SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA sequencing-based Afirma Medullary Thyroid Cancer (MTC) Classifier demonstrated high sensitivity and specificity in identifying MTC among pre-operative thyroid … [Read more…]

CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market … [Read more…]

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. … [Read more…]

BOULDER, Colo.–(BUSINESS WIRE)–$CLVS–Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at … [Read more…]

PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022. Conference Call and Webcast Details Investors may access a live audio webcast on the … [Read more…]

Company Remains Focused on Finding a Licensee for This Proprietary Cyclosporine Platform and is Encouraged by the Significant Interest to Date MISSION VIEJO, Calif.–(BUSINESS WIRE)–Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy, announces receiving its second patent for a novel cyclosporine dry … [Read more…]